<DOC>
	<DOCNO>NCT02628041</DOCNO>
	<brief_summary>High-dose rate brachytherapy ( HDRB ) use monotherapy emerge alternative Low-Dose Rate brachytherapy ( LDRB ) excellent PSA-progression free survival high 90-100 % favorable prostate cancer median follow-up 3-5 year . HDRB many advantage LDRB prospective dosimetry impact setup error , organ motion prostate swell treatment delivery . In addition , HDRB cause less acute late urinary toxicity compare LDRB . Acute urinary retention lead prolong catheterization , pericatheter urine leakage , urinary tract infection Trans-Urethral Resection Prostate result diminish quality life ( QOL ) increase psychological distress . The goal investigator ' phase II randomize study evaluate difference QOL urinary domain patient favourable intermediate risk extensive low-risk prostate cancer treat LDRB HDRB 3 month use Expanded Prostate Cancer Index Composite ( EPIC ) QOL score . The 3 month cut-off endpoint choose since HDRB-induced urinary toxicity subside 12 week compare 12 month LDRB . Secondary objective include : bowel sexual domain EPIC score International Prostate Symptom Score . The absolute PSA nadir prostate biopsy 36 month report assess local control .</brief_summary>
	<brief_title>HDR Brachytherapy vs. LDR Brachytherapy Monotherapy Localized Prostate Cancer</brief_title>
	<detailed_description>Primary Endpoint : • To evaluate difference QOL urinary domain patient treat Low-Dose Rate Brachytherapy ( LDRB ) High-Dose Rate Brachytherapy ( HDRB ) 3 month . Secondary Endpoints : - To compare LDRB vs. HDR relate Expanded Prostate Cancer Index Composite ( EPIC ) score bowel sexual domain baseline , 1 , 3 , 6 , 12 , 24 month . - To evaluate difference urinary function use IPSS , fill patient baseline , 1 , 3 , 6 , 12 24 month procedure . - To report acute long-term urinary , sexual gastro-intestinal toxicity use Common Terminology Criteria Adverse Events ( CTCAE ) version 4 patient 's visit . - To report dose bladder neck define 5 mm around Foley catheter bottom Foley balloon prostatic urethra volume least 2 cc . - To assess local control perform prostate rebiopsy radiotherapy 36 month assess treatment outcome . - The absolute Prostate Specific Antigen ( PSA ) nadir value report secondary objective PSA measurement every 6 month procedure .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate diagnose within last 9 month . Patients active surveillance evidence disease progression eligible protocol long meet eligibility criterion recent prostate biopsy ( within 9 month ) . Lowrisk disease define : Clinical stage T1T2 Gleason 6 PSA≤20 ng/mL . Intermediaterisk disease define : Clinical stage T1T2 Gleason 7 ( 3+4 ) PSA ≤ 20 ng/mL ≤ 60 % positive core . Lymph node evaluation either CT MRI optional leave discretion treat physician . No alpha reductase inhibitor use within 2 week randomization . A washout period 2 week require prior randomization . Eastern Cooperative Oncology Group status 01 No hormonal therapy accept . Prostate volume Transrectal Ultrasound ( TRUS ) ≤ 60 cc . Internation Prostate Symptom Score ( IPSS ) ≤ 20 ( alpha blocker allow ) Patients history malignancy , except : adequately treat nonmelanoma skin cancer , solid tumour curatively treat evidence disease ≥ 5 year . Prior current bleeding diathesis Previous androgen deprivation therapy within 6 month registration . Radical surgery carcinoma prostate , prior pelvic radiation , prior chemotherapy prostate cancer , prior Transurethral resection prostate ( TURP ) , prior cryosurgery prostate . Evidence metastatic disease ( radiology investigation discretion treat physician ) . Any serious active comorbid medical condition , laboratory abnormality , psychiatric illness , active uncontrolled infection , serious illness medical condition would prevent patient participate manage accord protocol ( accord investigator 's decision ) . Gleason score 7 ( 4+3 ) , clinical stage≥ T3a , PSA &gt; 20 &gt; 60 % positive core .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>High-Dose-Rate Brachytherapy</keyword>
	<keyword>HDR Monotherapy</keyword>
	<keyword>LDR monotherapy</keyword>
</DOC>